• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Life Sciences Investor Forum Agenda Announced for June 11th-12th

    6/10/25 2:38:09 PM ET
    $ATNM
    $BPTH
    $COCH
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNM alert in real time by email

    NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research.

    Individual investors, institutional investors, advisors, and analysts are invited to attend.

    REGISTER HERE

    It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management.

    "The life sciences sector is driving breakthrough innovation, and we're proud to give these pioneering companies a direct line to investors," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. "This Virtual Investor Conference, co-hosted by Zacks Small Cap Research, offers an essential platform for companies to share their vision, showcase scientific progress, and connect with a wider investment community actively seeking the next wave of healthcare and biotech leaders."

    June 11th

    Eastern

    Time (ET)
    PresentationTicker(s)
    1:00 PM ETNika Pharmaceuticals(OTCQB:NIKA)
    1:30 PM ETTivic Health Systems Inc.(NASDAQ:TIVC)
    2:00 PM ETAdia Nutrition, Inc.(OTCQB:ADIA)
    2:30 PM ET Sandoz Group AG(OTCQX:SDZNY, SIX: SDZ))



    June 12
    th

    Eastern

    Time (ET)
    PresentationTicker(s)
    9:00 AM ETCSL Ltd.(OTCQX:CSLLY, ASX: CSL))
    9:30 AM ETSharps Technology, Inc.(NASDAQ:STSS)
    10:00 AM ETHeidelberg Pharma AG(XETRA: HPHA)
    10:30 AM ETSBC Medical Group Holdings Incorporated(NASDAQ:SBC)
    11:00 AM ETActinium Pharmaceuticals, Inc.(NYSE:ATNM)
    11:30 AM ETImunon, Inc.(NASDAQ:IMNN)
    12:00 PM ETBio-Path Holdings, Inc.(OTCQB:BPTH)
    12:30 PM ETPerimeter Medical Imaging AI, Inc.(OTCQX:PYNKF, TSXV:PINK)
    1:00 PM ETMetaVia Inc.(NASDAQ:MTVA)
    2:00 PM ETConavi Medical Corp.(OTCQB:CNVIF, TSXV:CNVI)
    2:30 PM ETVycor Medical, Inc.(OTCQB:VYCO)
    3:00 PM ETEnvoy Medical, Inc.(NASDAQ:COCH)
    3:30 PM ETStarpharma Holdings Ltd.(OTCQX:SPHRY, ASX: SPL))



    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, [email protected]

    Virtual Investor Conferences Contact:

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    [email protected]



    Primary Logo

    Get the next $ATNM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATNM
    $BPTH
    $COCH
    $IMNN

    CompanyDatePrice TargetRatingAnalyst
    MetaVia Inc.
    $MTVA
    12/30/2024$12.00Buy
    H.C. Wainwright
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    8/7/2024$16.00 → $2.00Buy → Neutral
    B. Riley Securities
    Envoy Medical Inc.
    $COCH
    6/24/2024$8.50Buy
    Ascendiant Capital Markets
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    5/14/2024$25.00Overweight
    Stephens
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    9/6/2023$11.60Buy
    HSBC Securities
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    2/21/2023Outperform → Mkt Perform
    William Blair
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    9/8/2022$20.00Overweight
    Cantor Fitzgerald
    Actinium Pharmaceuticals Inc. (Delaware)
    $ATNM
    8/25/2022$16.00Buy
    B. Riley Securities
    More analyst ratings

    $ATNM
    $BPTH
    $COCH
    $IMNN
    SEC Filings

    See more
    • Sharps Technology Inc. filed SEC Form 8-K: Leadership Update

      8-K - Sharps Technology Inc. (0001737995) (Filer)

      7/3/25 4:34:13 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • SEC Form PRE 14A filed by Sharps Technology Inc.

      PRE 14A - Sharps Technology Inc. (0001737995) (Filer)

      7/3/25 4:15:17 PM ET
      $STSS
      Medical/Dental Instruments
      Health Care
    • Envoy Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities

      8-K - Envoy Medical, Inc. (0001840877) (Filer)

      7/2/25 4:31:22 PM ET
      $COCH
      Industrial Specialties
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Leadership Updates

    Live Leadership Updates

    See more
    • SBC Medical Appoints New Chief Marketing Officer to Enhance Marketing Infrastructure and Strengthen Brand Power

      IRVINE, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (NASDAQ:SBC) ("SBC Medical"), a global franchise and provider of services for aesthetic clinics, is pleased to announce the appointment of Shinya Inoue as Chief Marketing Officer (CMO), effective July 1, 2025. As CMO of SBC Medical, Mr. Inoue will lead efforts to enhance the brand value of the group's portfolio, including Shonan Beauty Clinic, one of Japan's largest aesthetic medical brands. He will also spearhead the evolution and optimization of the company's marketing infrastructure with a strong focus on digital innovation. Through strategic initiatives that address the increasing diversity of

      7/1/25 8:00:00 AM ET
      $SBC
      Medical/Nursing Services
      Health Care
    • Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team

      Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets From Statera Biopharma Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies. His key responsi

      2/24/25 8:15:00 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer

      Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology LAWRENCEVILLE, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the appointment of Douglas V. Faller, M.D., Ph.D., as chief medical officer, effective February 18, 2025. In this role, Dr. Faller will lead the company's clinical strategy including advancing its lead program IMNN-001 for the treatment of newly diagnosed advanced ovarian cancer, which is on track to enter a Phase 3 pivotal trial in the first quarter of 202

      2/10/25 8:05:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Envoy Medical Expands Global Patent Portfolio with New Issuances in Australia

      White Bear Lake, Minnesota--(Newsfile Corp. - July 1, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of three new patents, further strengthening its intellectual property portfolio in Australia.The Australian Patent Office has issued the following three patents to Envoy Medical Corporation:Australian Patent No. 2021391396 on April 24, 2025. The title of the patent is Implantable Cochlear Implant Stimulation Calibration. This patent relates to cochlear implant systems having a testing circuit that determines an amount of current provided by a source element

      7/1/25 8:00:00 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • SBC Medical Appoints New Chief Marketing Officer to Enhance Marketing Infrastructure and Strengthen Brand Power

      IRVINE, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (NASDAQ:SBC) ("SBC Medical"), a global franchise and provider of services for aesthetic clinics, is pleased to announce the appointment of Shinya Inoue as Chief Marketing Officer (CMO), effective July 1, 2025. As CMO of SBC Medical, Mr. Inoue will lead efforts to enhance the brand value of the group's portfolio, including Shonan Beauty Clinic, one of Japan's largest aesthetic medical brands. He will also spearhead the evolution and optimization of the company's marketing infrastructure with a strong focus on digital innovation. Through strategic initiatives that address the increasing diversity of

      7/1/25 8:00:00 AM ET
      $SBC
      Medical/Nursing Services
      Health Care
    • IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq's Listing Requirement, Anticipates Additional Compliance Period

      LAWRENCEVILLE, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that, in consultation with The Nasdaq Stock Market LLC (Nasdaq), it has submitted its plan to Nasdaq to regain compliance with the minimum bid price requirement and the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. On May 29, 2025, the Company requested a hearing before The Nasdaq Hearings Panel ("Panel"). At this hearing, the Company will request an extension to meet the requirements and return to compliance. In an exchange with Nasdaq, the Company has established

      6/30/25 8:00:00 AM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Patel Mona Chetan bought $3,675 worth of shares (2,500 units at $1.47), increasing direct ownership by 14% to 20,000 units (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      6/13/25 4:10:30 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Director Patel Mona Chetan bought $14,600 worth of shares (10,000 units at $1.46), increasing direct ownership by 133% to 17,500 units (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      6/10/25 4:11:23 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Chief Financial Officer Woodworth Marshall H bought $9,940 worth of shares (14,200 units at $0.70), increasing direct ownership by 47% to 44,279 units (SEC Form 4)

      4 - MetaVia Inc. (0001638287) (Issuer)

      6/4/25 4:01:12 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Potashnick Robert

      3 - Envoy Medical, Inc. (0001840877) (Issuer)

      7/3/25 2:48:15 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Director Glickman Mark A was granted 28,147 shares, increasing direct ownership by 289% to 37,887 units (SEC Form 4)

      4 - MetaVia Inc. (0001638287) (Issuer)

      7/1/25 4:03:19 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Groves Jason L was granted 28,147 shares, increasing direct ownership by 160% to 45,699 units (SEC Form 4)

      4 - MetaVia Inc. (0001638287) (Issuer)

      7/1/25 4:02:49 PM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on MetaVia with a new price target

      H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00

      12/30/24 7:25:48 AM ET
      $MTVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinum Pharma downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded Actinum Pharma from Buy to Neutral and set a new price target of $2.00 from $16.00 previously

      8/7/24 12:40:34 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ascendiant Capital Markets initiated coverage on Envoy Medical with a new price target

      Ascendiant Capital Markets initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $8.50

      6/24/24 7:29:10 AM ET
      $COCH
      Industrial Specialties
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Imunon Inc.

      SC 13G - Imunon, Inc. (0000749647) (Subject)

      11/14/24 5:37:34 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Imunon Inc.

      SC 13G/A - Imunon, Inc. (0000749647) (Subject)

      11/14/24 12:17:50 PM ET
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Envoy Medical Inc.

      SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

      11/14/24 8:49:34 AM ET
      $COCH
      Industrial Specialties
      Health Care

    $ATNM
    $BPTH
    $COCH
    $IMNN
    Financials

    Live finance-specific insights

    See more
    • Bio-Path Holdings Provides Clinical and Operational Update

      HOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced highlights from the recent clinical development and operational update conference call and webcast held May 26, 2025. An archived webcast of the event can be accessed here. "Our business model centers around generating new drug candidates from our DNAbilize® platform and licensing them for final development and commercialization with partners that have expertise and scale to successfully bring them to market," sa

      6/3/25 7:00:00 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025

      HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 29, 2025 at 8:30 a.m. ET to provide a comprehensive business overview. To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company's website, www.biopathho

      5/22/25 4:30:00 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation

      Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m. EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced financial results for the first quarter ended March 31, 2025 and outlined operational highlights based on its newly expanded clinical pipeline. "This is a defining time for the company. During the quarter we initiated a significant strategic shift, dramatically expanding Tivic's clinical pipeline for restoring immune system health," stated Tivic CEO Jennifer Ernst. "In February, we executed a comprehensive worldwide exclusive licensing agreement for the Phase III TLR5 agonist, Entolimod and its molecular derivative, Ent

      5/15/25 4:05:00 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care